Presentation TCT 2021 Oral Anticoagulation Should Be the Default Strategy After LAAC Presenter: Matthew J. Price November 06, 2021
Presentation TCT 2021 Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond Presenter: Connie Hess November 06, 2021
Presentation TCT 2021 PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation Presenter: Pavel Osmancik November 05, 2021
Presentation TCT 2021 Controversies Surrounding Transcatheter Devices: Durability, Anticoagulation, Conduction, and More Presenter: Josep Rodés-Cabau November 04, 2021
Presentation TCT 2021 TCT 703: Concomitant Transcatheter Mitral-Valve-in-Valve (MViV) with Left Atrial Appendage (LAA) Occlusion Device in a High-Risk Patient Unable to Tolerate Anticoagulation Presenter: Peter Sayegh November 04, 2021
Presentation TVT 2021 Percutaneous Left Atrial Appendage Closure Versus Oral Anticoagulation for Non-Valvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Presenter: Yousif Ahmad July 22, 2021